Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Long Term Incentive Scheme

7 Dec 2007 07:00

Futura Medical PLC07 December 2007 For immediate release 7 December 2007 Futura Medical Plc ("Futura" or "the Company") Long Term Incentive Scheme Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovativeproducts for the consumer healthcare market, announces the introduction of along term incentive scheme for the Executive Directors under which shares willbe awarded subject to the achievement of key milestone events at the Company. The Board believes that this Long Term Incentive Scheme ("LTIS"), which has beendeveloped and reviewed over the past 12 months, is in the interests of allshareholders as it aligns the interests of the Company's Directors with those ofall other shareholders. The Executive Directors currently have beneficial interests in 1,062,687 Futurashares representing 1.8% of the Company's issued share capital and also holdexisting options over 350,000 Futura shares which currently represent 0.6% ofthe Company's issued share capital before the introduction of this LTIS. Therehave been no new grants of options to Directors since 22 March 2005. The actual quantum of the awards received by the Executive Directors will dependon achieving set milestones and the share price at the time relative to targetsset in advance. As a guide, if all the approved milestones are achieved at theshare price targets over the next 36 months then the additional shares issued inafter tax settlement would be equivalent to approximately 1.3% of the currentshare capital. The detailed scheme rules will be available shortly on theCorporate Governance pages of the Company's website. For any further information please contact:Futura Medical plcJames Barder, Chief Executive Tel: +44 (0) 1483 685 670mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk Canaccord Adams Tel: +44 (0) 20 7050 6500Mark Ashurst / Adria Da Breo For any media enquiries please contact:Buchanan Communications Tel: +44 (0) 020 7466 5000Mark Court / Rebecca Dietrich Notes Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products forconsumer healthcare. The Company is developing a portfolio of products and itsstrategy is to license their manufacture and distribution to majorpharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market ofthe London Stock Exchange. www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
24th Apr 20257:00 amRNSChange of Broker
15th Apr 20257:00 amRNSResults for the Year ended 31 December 2024
10th Apr 20251:30 pmRNSNotice of Results and Investor Presentation
31st Mar 20257:00 amRNSBoard Appointment
30th Jan 20257:00 amRNSFY24 Trading Update and FY25 Outlook
15th Jan 20257:00 amRNSPositive results from WSD4000 Home User study
13th Jan 20257:00 amRNSRemuneration of Non-Executive Directors and TVR's
20th Dec 20247:58 amRNSHolding(s) in Company
2nd Dec 20247:00 amRNSBlock Listing Six Monthly Return
15th Nov 20247:00 amRNSTR-1: Notification of major holdings
4th Nov 20247:00 amRNSEncouraging New Product Development Pipeline
31st Oct 20247:00 amRNSTotal Voting Rights
7th Oct 20247:00 amRNSFurther milestone payment triggered post US launch
1st Oct 20247:00 amRNSTotal Voting Rights
13th Sep 20247:00 amRNSDirectors’ / PDMR Dealing
11th Sep 20245:43 pmRNSTrinity Delta research note & consensus forecasts
10th Sep 20247:00 amRNSFutura Medical - Interim Results 2024
2nd Sep 202410:47 amRNSUpdate on US Launch
2nd Sep 20247:00 amRNSUpdate on US launch
19th Aug 20247:00 amRNSNotice of Results
1st Aug 20247:05 amRNSUpdate on US launch
1st Jul 20242:13 pmRNSTotal Voting Rights
1st Jul 20247:00 amRNSNominated Adviser and Joint Broker
20th Jun 20244:12 pmRNSResult of AGM
20th Jun 20247:00 amRNSAGM Statement
31st May 20247:00 amRNSBlock Listing Six Monthly Review
24th May 20247:00 amRNSNotice of AGM and availability of Annual Report
29th Apr 20247:00 amRNSDirectors’ / PDMR Dealing and Grant of Options
10th Apr 20247:00 amRNSResults for the Year ended 31 December 2023
25th Mar 20247:00 amRNSNotice of Results and Investor Presentation
14th Feb 20247:00 amRNSEroxon to be available on prescription
6th Feb 20247:01 amRNSTrading Update
6th Feb 20247:00 amRNSAppointment of Joint Corporate Broker
17th Jan 20247:00 amRNSDirector/PDMR Dealing
17th Jan 20247:00 amRNSRemuneration of Non-Exec Directors & Voting Rights
15th Jan 20247:00 amRNSFutura Medical extends collaboration with Cooper
9th Jan 20247:00 amRNSAppointment of Roy Davis as Non-Executive Director
30th Nov 20233:10 pmRNSTotal Voting Rights
30th Nov 20233:10 pmRNSBlock Listing Six Monthly Return
7th Nov 20237:00 amRNSFutura expands partnership with M8 Pharmaceuticals
2nd Nov 20233:34 pmRNSEroxon Awarded “New Product of the Year” by Boots
31st Oct 20237:00 amRNSBlock Listing Application and Total Voting Rights
25th Oct 20237:00 amRNSEroxon® Granted Marketing Authorisation in Mexico
19th Oct 20237:00 amRNSEroxon Launches in the United Arab Emirates
10th Oct 20237:00 amRNSDirectors’/PDMR Dealing and Grant of Options
2nd Oct 20237:00 amRNSEuropean Patent Granted for MED3000 until 2040
18th Sep 20237:00 amRNSFutura Medical - Interim Results 2023
18th Aug 20237:00 amRNSFutura Medical - Notice of Interim Results
31st Jul 20237:00 amRNSFutura Medical - Total Voting Rights
18th Jul 202311:04 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.